Bank of New York Mellon’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-28,412
| Closed | -$84K | – | 4362 |
|
|
2016
Q3 | $84K | Sell |
28,412
-4,804
| -14% | -$8.32K | ﹤0.01% | 4078 |
|
|
2016
Q2 | $49K | Sell |
33,216
-101,800
| -75% | -$233K | ﹤0.01% | 4177 |
|
|
2016
Q1 | $499K | Buy |
135,016
+1,254
| +0.9% | +$7.77K | ﹤0.01% | 3438 |
|
|
2015
Q4 | $1.35M | Sell |
133,762
-32,159
| -19% | -$387K | ﹤0.01% | 2964 |
|
|
2015
Q3 | $2.26M | Sell |
165,921
-9,910
| -6% | -$176K | ﹤0.01% | 2663 |
|
|
2015
Q2 | $3.33M | Sell |
175,831
-15,751
| -8% | -$341K | ﹤0.01% | 2597 |
|
|
2015
Q1 | $5.01M | Buy |
191,582
+8,461
| +5% | +$215K | ﹤0.01% | 2315 |
|
|
2014
Q4 | $3.83M | Buy |
183,121
+7,339
| +4% | +$185K | ﹤0.01% | 2451 |
|
|
2014
Q3 | $5.87M | Buy |
175,782
+10,463
| +6% | +$325K | ﹤0.01% | 2215 |
|
|
2014
Q2 | $5.3M | Buy |
165,319
+6,227
| +4% | +$232K | ﹤0.01% | 2294 |
|
|
2014
Q1 | $7.35M | Sell |
159,092
-14,513
| -8% | -$851K | ﹤0.01% | 2091 |
|
|
2013
Q4 | $12.3M | Buy |
173,605
+8,825
| +5% | +$675K | ﹤0.01% | 1753 |
|
|
2013
Q3 | $14.1M | Buy |
164,780
+20,595
| +14% | +$1.75M | ﹤0.01% | 1620 |
|
|
2013
Q2 | $9.13M | Buy |
+144,185
| New | +$7.66M | ﹤0.01% | 1836 |
|
Bank of New York Mellon's AEGR Position: Q4 2016 in Review
Bank of New York Mellon sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 28,412 shares — an estimated $84K sold.
Bank of New York Mellon first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $14.1M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Bank of New York Mellon reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Bank of New York Mellon sold 28,412 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $84K.
- Bank of New York Mellon first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Bank of New York Mellon's Aegerion Pharmaceuticals position peaked at $14.1M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Bank of New York Mellon's 13F filing for Q4 2016, filed 13 Feb 2017.